Advertisement
Advertisement
Menopur

Menopur

Manufacturer:

Ferring

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Highly purified menotrophin corresponding to 75, 600 & 1,200 IU FSH & 75, 600 & 1,200 IU LH
Indications/Uses
Anovulation including polycystic ovarian disease (PCOD) in women unresponsive to treatment w/ clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART) [eg, in vitro fertilisation/embryo transfer (IVF/ET)], gamete intra-fallopian transfer (GIFT) & intracytoplasmic sperm inj (ICSI). Stimulation of follicular growth in females w/ hypo- or normogonadotropic ovarian insufficiency.
Dosage/Direction for Use
SC/IM Women w/ anovulation (including PCOD) Therapy should start w/in the initial 7 days of the menstrual cycle. Initially 75-150 IU daily, maintained for at least 7 days. Recommended dose increment: 37.5 IU/adjustment up to 75 IU. Max daily dose: 225 IU. Women undergoing controlled ovarian hyperstimulation for multiple follicular development for ART, GIFT & ICSI Therapy should start approx 2 wk after the start of agonist treatment. Initially 150-225 IU daily for at least 1st 5 days of treatment. Dose adjustment should not exceed >150 IU/adjustment. Max daily dose: 450 IU daily. Max duration: 20 days. Women w/ hypo- or normogonadotropic ovarian insufficiency Initially 75-150 IU daily. Dose may be increased gradually until there is evidence of estradiol secretion or follicular growth. Maintain dose until pre-ovulation estradiol serum level is achieved. To induce ovulation, administer 5,000-10,000 IU hCG via IM inj 1-2 days after the last dose of HMG.
Contraindications
Hypersensitivity. Pituitary or hypothalamic tumours. Ovarian, uterine or mammary carcinoma; gynaecological haemorrhage of unknown aetiology; ovarian cysts or enlarged ovaries not due to PCOD. Primary ovarian failure; malformation of sexual organs or fibroid tumours of the uterus incompatible w/ pregnancy. Pregnancy & lactation.
Special Precautions
Perform 1st inj under direct supervision. Assess fertility & evaluate for hypothyroidism, adrenocortical deficiency, hyperprolactinemia & pituitary or hypothalamic tumours prior to treatment. Possible ovarian enlargement or hyperstimulation development. Discontinue gonadotrophin treatment if severe ovarian hyperstimulation syndrome (OHSS) occurs. Potential risk of multiple pregnancy, pregnancy loss by miscarriage or abortion, ectopic pregnancy, reproductive system neoplasms, congenital malformation & thromboembolic events. No relevant use in the paed population. 75 IU: Renal & hepatic impairment. Elderly.
Adverse Reactions
Abdominal pain & distension, nausea; inj site reactions; headache; OHSS, pelvic pain.
Drug Interactions
May enhance follicular response w/ clomiphene citrate.
MIMS Class
Trophic Hormones & Related Synthetic Drugs
ATC Classification
G03GA02 - human menopausal gonadotrophin ; Belongs to the class of gonadotropins. Used as ovulation stimulants.
Presentation/Packing
Form
Menopur powd for inj 1,200 IU
Packing/Price
(+ 2 pre-filled syringe w/ solvent) 1's
Form
Menopur powd for inj 600 IU
Packing/Price
(+ 1 pre-filled syringe w/ solvent) 1's
Form
Menopur powd for inj 75 IU
Packing/Price
(+ 10 amp solvent) 10 × 1's; (+ 5 amp solvent) 5 × 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement